Phase 1 study to evaluate the safety and tolerability of the CD40 agonistic monoclonal antibody APX005M in subjects with solid tumors. Background: IPI-549 is a potential first-in-class potent and ...
This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This abstract does not include a full text component.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results